1. Mesman RLS, Calléja FM, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H and MP Vreeswijk. The functional impact of variants of uncertain significance in BRCA2. Genetics in Medicine (2018), in press.

2. Shimelis H, Mesman RL, …, Vrieling H, Monteiro AN, Goldgar DE, Carreira A, Vreeswijk MP and FJ Couch, BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. (2017) Jun 1;77(11):2789-2799.

3. Boei JJ, Vermeulen S, Klein B, Hiemstra PS, Verhoosel RM, Jennen DG, Lahoz A, Gmuender H, Vrieling H. Xenobiotic metabolism in differentiated human bronchial epithelial cells. Arch Toxicol. (2017) May;91(5):2093-2105. doi: 10.1007/s00204-016-1868-7.

4. Hendriks G, Derr RS, Misovic B, Morolli B, Calléja FM, Vrieling H. The extended ToxTracker assay discriminates between induction of DNA damage, oxidative stress and protein misfolding. Toxicol Sci. (2016) Mar;150(1):190-203. doi: 10.1093/toxsci/kfv323.

5. Hendriks G, Morolli B, Calléja FM, Plomp A, Mesman RL, Meijers M, Sharan SK, Vreeswijk MP, Vrieling H. An Efficient Pipeline for the Generation and Functional Analysis of Human BRCA2 Variants of Uncertain Significance. Hum Mutat. (2014) Nov;35(11):1382-91.

6. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens J, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter J, Vreeswijk M, Jager A, van Gent DC. Functional ex vivo assay to select Homologous Recombination deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. (2014) Sep 15;20(18):4816-26

All publications